Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| (ATH22-24) | Other Identifier | Dr. Stavroula Rakitzi private practice |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia.
Is it effective and efficacious?
Individuals with schizophrenia and treatment resistant schizophrenia will participate on a group cognitive behavioral therapy and rehabilitation, in which Integrated Psychological Therapy and Metacognitive Training are going to be implemented. The therapy will last 60 biweekly sessions. This is a non randomized trial.
Speed of processing, working memory, verbal memory, visual memory, reasoning and problem solving, social cognition, symptoms, functional outcome and recovery will be evaluated before, after therapy and in a 6 months follow up.
MCCB, Social Perception Scale, the Greek Test for verbal memory, PANSS, WHO DAS 2. 0 (Greek), PSYRAT and the Recovery Assessment Scale will be used ih this study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Therapy Group A | Experimental | Therapy Group A Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 5 individuals with schizophrenia |
|
| Therapy Group B | Experimental | Therapy Group B Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 2 individuals with schizophrenia |
|
| Therapy Group C | Experimental | Therapy Group C Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 8 |
|
| Therapy Group D | Experimental | Therapy Group D Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 8 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia | Combination Product | The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. |
| Measure | Description | Time Frame |
|---|---|---|
| Cognitive Functions: Matrics Consensus Cognitive Battery (MCCB), Greek Verbal Test | Greek verbal memory test: (verbal memory semantic condition (average) (minimum 0-maximum 40) (high scores better outcomes) MCCB: (Neuropsychological Assessment Battery) (NAB) (reasoning and problem solving): (minimum 0 maximum 26) (high scores better outcomes) Data is analyzed through SPS 13. | Baseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks) |
| Symptoms, PANSS Greek Version | (PANSS) Greek Version Positive symptoms (minimum 8 maximum 49) low scores better outcomes Negative symptoms: (minimum 8 maximum 49) low scores better outcomes General Psychopathology: (minimum 17 maximum 112) low scores better outcomes Total: Sum of positive, negative and general symptoms (minimum 31, maximum 210), low scores better outcomes The total score is used in the statistical analysis (PSYRAT) Auditory hallucinations (minimum 0 maximum 44) low scores better Delusion (minimum 0 maximum 24) low scores better Data is analyzed with SPSS 13 | Baseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks) |
| Functional Outcome | WHO DAS 2.0 WHODAS total: (functional outcome) (minimum 0-maximum 100) low scores better outcomes Data are analyzed with SPSS 13 | Baseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks) |
| Recovery | RAS-DS scale Total score (sum of the scores) (0-152) high scores are better outcomes Data is analyzed through SPSS 13 | Baseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| Intelligent Quotient | Intelligence, high scores are better Data is analyzed through SPSS 13. | Baseline T1 (preintervention) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stavroula Rakitzi, Dr. | Private Practice | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stavroula Rakitzi | Athens | 15771 | Greece |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35320347 | Background | Penney D, Sauve G, Mendelson D, Thibaudeau E, Moritz S, Lepage M. Immediate and Sustained Outcomes and Moderators Associated With Metacognitive Training for Psychosis: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022 May 1;79(5):417-429. doi: 10.1001/jamapsychiatry.2022.0277. | |
| Background | Rakitzi, S., Georgila, P., Becker-Woitag, A.P. (2021). The recovery process for individuals with schizophrenia in the context of evidence based psychotherapy and rehabilitation. A systematic review. European Psychologist, 26(2), 96-111 doi/pdf/10.1027/1016-9040/a000400. | ||
| 31385737 |
| Label | URL |
|---|---|
| linkedin Stavroula Rakitzi | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
35 patients with schizophrenia started
November 2022-Januar 2023 Patients were recruited from our private practice Dr. Stavroula Rakitzi Dr. Polyxeni Georgila
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Therapy Group A | Therapy Group A Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. Monthly psychiatric treatment twice a week IPT and MCT, 60 minutes every session
The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: November 2022-June 2023 Preevaluation: 1 November 2022 Postevaluation: June 2023 Follow up evaluation Januar 2024 |
| Title | Milestones | Reasons Not Completed | ||||
|---|---|---|---|---|---|---|
| T1-T2 (11-2022-6 2023, 1 2023- 8 2023) |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 15, 2024 |
Not provided
Not provided
Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented
Not provided
Not provided
Not provided
| Therapy Group E | Experimental | Therapy Group E Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 3 |
|
| Therapy Group F | Experimental | Therapy Group F Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 3 |
|
| Therapy Group G | Experimental | Therapy Group G Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented 3 |
|
| Therapy Group H | Experimental | Therapy Group H Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 3 |
|
|
|
| Background |
| Rakitzi S, Georgila P. Integrated Psychological Therapy and Treatment-Resistant Schizophrenia: Initial Findings. Psychiatry. 2019 Winter;82(4):354-367. doi: 10.1080/00332747.2019.1616658. Epub 2019 Aug 6. |
| 27280523 | Result | Rakitzi S, Georgila P, Efthimiou K, Mueller DR. Efficacy and feasibility of the Integrated Psychological Therapy for outpatients with schizophrenia in Greece: Final results of a RCT. Psychiatry Res. 2016 Aug 30;242:137-143. doi: 10.1016/j.psychres.2016.05.039. Epub 2016 May 30. |
| Result | Nuecterlein, K. H., & Green, M. F. (2006). MCCB. MATRICS Consensus Cognitive Battery. LA: MATRICS Assessment Inc. |
| Result | Fuentes, I., Garcia, S., Ruiz, J.C., Soler, J., & Roder, V. (2007). Social perception scale in Schizophrenia. A pilot study. International Journal of Psychology and Psychological therapy, 7 (1), 1-12. |
| Result | Kosmidou, M., & Vlahou, C. (2010). Greek verbal memory test. Athens: Parisianos. |
| Result | Lykouras, L., Botsis, A., & Oulis, P. (2005). Greek version of PANSS. Athens: Scientific publications. |
| 10473315 | Result | Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med. 1999 Jul;29(4):879-89. doi: 10.1017/s0033291799008661. |
| Result | Hancock, N., Scanlan, J.N., Bundy, A.C., & Honey A. (2019). Recovery Assessment Scale -Domains & Stages (RAS-DS) Manual- Version 3. Sydney: University of Sydney. |
| Result | Koumpouros, Y., Papageorgiou, E., Sakellari, E. et al. (2018). Adaptation and psychometric properties' evaluation of the Greek version of WHODAS 2.0. Pilot application in Greek elderly population. Health Services and Outcomes Research Methodology,18(1), 63-74. https://doi.org/10.1007/s10742-017-0176-x. |
| Result | Aster, M., Neubauer, M., & Horn, R. (2006). Wechsler-Intelligenztest für Erwachsene WIE. Frankfurt: Harcourt Test Services |
| orcid: 0000-0002-5231-6619 | View source |
| FG001 | Therapy Group B | Therapy Group B Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. Monthly psychiatric treatment twice a week IPT and MCT, 60 minutes every session The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: November 2022-June 2023 Preevaluation: 1 November 2022 Postevaluation: June 2023 Follow up evaluation Januar 2024
|
| FG002 | Therapy Group C | Therapy Group C Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. Monthly psychiatric treatment twice a week IPT and MCT, 60 minutes every session The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: November 2022-June 2023 Preevaluation: 1 November 2022 Postevaluation: June 2023 Follow up evaluation Januar 2024
|
| FG003 | Therapy Group D | Therapy Group D Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. Monthly psychiatric treatment twice a week IPT and MCT, 60 minutes every session The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: Januar 2023-August 2023 Preevaluation: December 2022 Postevaluation: August 2023 Evaluation in follow up: March 2024
|
| FG004 | Therapy Group E | Therapy Group E Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. Monthly psychiatric treatment twice a week IPT and MCT, 60 minutes every session The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: Januar 2023-August 2023 Preevaluation: December 2022 Postevaluation: August 2023 Evaluation in follow up: March 2024
|
| FG005 | Therapy Group F | Therapy Group F Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. Monthly psychiatric treatment twice a week IPT and MCT, 60 minutes every session The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: Januar 2023-August 2023 Preevaluation: December 2022 Postevaluation: August 2023 Evaluation in follow up: March 2024
|
| FG006 | Therapy Group G | Therapy Group G Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented Monthly psychiatric treatment twice a week IPT and MCT, 60 minutes every session The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: Januar 2023-August 2023 Preevaluation: December 2022 Postevaluation: August 2023 Evaluation in follow up: March 2024
|
| FG007 | Therapy Group H | Therapy Group H Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. Monthly psychiatric treatment twice a week IPT and MCT, 60 minutes every session The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: Januar 2023-August 2023 Preevaluation: December 2022 Postevaluation: August 2023 Evaluation in follow up: March 2024
|
|
| COMPLETED | 34 |
|
| NOT COMPLETED |
|
|
| T1-T3 (11-2022-1-2024; 1 2023-3 2024) |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Therapy Group All Participants (Groups A, B, C, D, E, F, G, H) | Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 35 individuals with schizophrenia The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. The Groups A, B, C, D, E, F, G, H have been added to one group. They receive the same intervention. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Mean | Standard Deviation | Years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Race/Ethnicity, Customized | Number | Greek patients |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
| ||||||||||||||||||
| WAIS, IQ | Mean | Standard Deviation | Units on a scale |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Cognitive Functions: Matrics Consensus Cognitive Battery (MCCB), Greek Verbal Test | Greek verbal memory test: (verbal memory semantic condition (average) (minimum 0-maximum 40) (high scores better outcomes) MCCB: (Neuropsychological Assessment Battery) (NAB) (reasoning and problem solving): (minimum 0 maximum 26) (high scores better outcomes) Data is analyzed through SPS 13. | All participants in T1, T3. All participants participate in the same therapy | Posted | Mean | Standard Deviation | score on a scale | Baseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks) |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Symptoms, PANSS Greek Version | (PANSS) Greek Version Positive symptoms (minimum 8 maximum 49) low scores better outcomes Negative symptoms: (minimum 8 maximum 49) low scores better outcomes General Psychopathology: (minimum 17 maximum 112) low scores better outcomes Total: Sum of positive, negative and general symptoms (minimum 31, maximum 210), low scores better outcomes The total score is used in the statistical analysis (PSYRAT) Auditory hallucinations (minimum 0 maximum 44) low scores better Delusion (minimum 0 maximum 24) low scores better Data is analyzed with SPSS 13 | Evaluation of T1, T3. All participants participate in the same therapy | Posted | Mean | Standard Deviation | score on a scale | Baseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Functional Outcome | WHO DAS 2.0 WHODAS total: (functional outcome) (minimum 0-maximum 100) low scores better outcomes Data are analyzed with SPSS 13 | All participants in T1, T3. All participants participate in the same therapy. | Posted | Mean | Standard Deviation | score on a scale | Baseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Recovery | RAS-DS scale Total score (sum of the scores) (0-152) high scores are better outcomes Data is analyzed through SPSS 13 | All participants in T1, T3. All participants participate in the same therapy. | Posted | Mean | Standard Deviation | score on a scale | Baseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Intelligent Quotient | Intelligence, high scores are better Data is analyzed through SPSS 13. | Pre-intervention | Posted | Mean | Standard Deviation | score on a scale IQ | Baseline T1 (preintervention) |
|
|
November 2022-March 2024. Adverse events were evaluated monthly, from Novemeber 2022-March 2024, for every participant.
Our systematic assessment during the study highlighted no risk for serious adverse events, for mortality or for other adverse events
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Therapy Group A | Therapy Group A Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 5 individuals with schizophrenia The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: November 2022-June 2023 Preevaluation: October 2022 Postevaluation: June 2023 Follow up evaluation Januar 2024 5 assessed for serious adverse events, 0 affected | 0 | 5 | 0 | 5 | 0 | 5 |
| EG001 | Therapy Group B | Therapy Group B Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 2 individuals with schizophrenia The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: November 2022-June 2023 Preevaluation: October 2022 Postevaluation: June 2023 Follow up evaluation Januar 2024 2 assessed for serious adverse events, 0 affected | 0 | 2 | 0 | 2 | 0 | 2 |
| EG002 | Therapy Group C | Therapy Group C Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 8 The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: November 2022-June 2023 Preevaluation: October 2022 Postevaluation: June 2023 Follow up evaluation Januar 2024 8 assessed for serious adverse events, 0 affected | 0 | 8 | 0 | 8 | 0 | 8 |
| EG003 | Therapy Group D | Therapy Group D Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 8 The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: Januar 2023-August 2023 Preevaluation: December 2022 Postevaluation: August 2023 Evaluation in follow up: March 2024 8 assessed for serious adverse events, 0 affected | 0 | 8 | 0 | 8 | 0 | 8 |
| EG004 | Therapy Group E | Therapy Group E Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 3 The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: Januar 2023-August 2023 Preevaluation: December 2022 Postevaluation: August 2023 Evaluation in follow up: March 2024 3 assessed for serious adverse events, 0 affected | 0 | 3 | 0 | 3 | 0 | 3 |
| EG005 | Therapy Group F | Therapy Group F Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 3 The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: Januar 2023-August 2023 Preevaluation: December 2022 Postevaluation: August 2023 Evaluation in follow up: March 2024 3 assessed for serious adverse events, 0 affected | 0 | 3 | 0 | 3 | 0 | 3 |
| EG006 | Therapy Group G | Therapy Group G Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented 3 The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: Januar 2023-August 2023 Preevaluation: December 2022 Postevaluation: August 2023 Evaluation in follow up: March 2024 3 assessed for serious adverse events, 0 affected | 0 | 3 | 0 | 3 | 0 | 3 |
| EG007 | Therapy Group H | Therapy Group H Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 3 The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia: The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia. Therapy period: Januar 2023-August 2023 Preevaluation: December 2022 Postevaluation: August 2023 Evaluation in follow up: March 2024 3 assessed for serious adverse events, 0 affected | 0 | 3 | 0 | 3 | 0 | 3 |
Not provided
Not provided
No limitations
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Stavroula Rakitzi | Private practice | 6989766935 | srakitzi@gmail.com |
| Nov 15, 2024 |
| Prot_SAP_005.pdf |
| ICF | No | No | Yes | Informed Consent Form | Nov 15, 2024 | Nov 15, 2024 | ICF_006.pdf |
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D000090663 | Schizophrenia, Treatment-Resistant |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| D012046 | Rehabilitation |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
| D000359 | Aftercare |
| D003266 | Continuity of Patient Care |
| D005791 | Patient Care |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |
Not provided
Not provided
| Title | Measurements |
|---|---|
|
| Problem-solving (NAB) T3 |
|
Bonferroni correction p<.05 F(2)=7.30 η=.213 (P<.05)
| Superiority |
|
|
|
|
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
|